by Endobronchial ultrasound biopsy (EBUS) is a minimally invasive biopsy procedure used to diagnose lung cancer and other lung diseases. EBUS uses an ultrasound probe passed through the bronchoscope to visualize structures around the airways and lymph nodes in the chest. By incorporating a biopsy needle through its working channel, it allows physicians to extract samples from suspicious lesions under real-time ultrasound guidance. EBUS has revolutionized lung cancer staging with much higher accuracy compared to conventional techniques for assessing the spread of disease to lymph nodes. It is especially helpful for cancers at the centre of the chest which are difficult to access through other techniques.
The global Endobronchial Ultrasound Biopsy Market is estimated to be valued at US$ 722.67 Bn in 2023 and is expected to exhibit a CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
The rising incidence of lung cancer worldwide is a key driver of the EBUS biopsy market’s growth. Lung cancer is the leading cause of cancer mortality accounting for over 1.8 million new cases and 1.6 million deaths each year globally. EBUS has emerged as an important diagnostic tool for accurate lung cancer staging to determine the optimal treatment approach and prognosis. Technological advancements expanding the clinical applications of EBUS are expected to further boost its adoption. Next generation ultrasound probes and AI-powered analysis of ultrasound images are paving the way for improved target visualization, diagnosis and lymph node mapping. This will enhance EBUS’ utility beyond lung cancer to assess other intrathoracic lesions and diseases such as sarcoidosis.
Porter’s Analysis
Threat of new entrants: Moderate. Substantial capital is required for R&D and manufacturing of endobronchial ultrasound biopsy equipment. However, opportunity is moderate given growing market demand.
Bargaining power of buyers: Moderate. Many hospitals consolidate purchasing to leverage volume discounts. However, need for specialized equipment limits alternatives.
Bargaining power of suppliers: Low. Key components have many suppliers. suppliers have low differentiation.
Threat of new substitutes: Low. No close substitute for endobronchial ultrasound biopsy in diagnosing lung cancers and other respiratory diseases currently exists.
Competitive rivalry: High. Intense competition among major players to gain market share through new product launches and geographic expansion.
Key Takeaways
The global Endobronchial Ultrasound Biopsy Market Share is expected to witness high growth.
Regional analysis: North America dominates the market currently due to developed healthcare infrastructure and growing incidence of lung cancer. However, Asia Pacific is expected to witness the fastest growth over the forecast period supported by rising medical tourism and healthcare spending.
Key players operating in the Endobronchial Ultrasound Biopsy market are Alf Engineering, F-TECH, Magna International, Metalsa, Nissin Kogyo, Sango Co., Ltd., Tata Precision Tubes, Tenneco, Thyssenkrupp AG, Vari-Form, and Yorozu. Key players are focusing on new product launches and partnerships to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
